Probenecid has been shown to competitively inhibit the excretion of penicillin and cephalosporins by the tubules of the kidneys (6) . In a previous publication, we reported the pharmacokinetics of cefamandole after intramuscular (i.m.) and intravenous injection (3) . The data in this paper illustrate the effect of probenecid on the serum levels and urinary excretion of cefamandole.
MATERIALS AND METHODS Antibiotic. The lithium salt of cefamandole as standard powder was supplied in 20-mg ampoules by Eli Lilly & Co., Indianapolis, Ind. The cefamandole for clinical use, CT-2883-4F, was cefamandole nafate furnished as 1 g of cefamandole activity per ampoule.
Subjects. Twelve male volunteers between the ages of 25 and 55 years were admitted to the study after being screened by history and physical examination and laboratory determination of blood, renal, and liver function. Informed written consent was obtained.
Injection of antibiotic. For i.m. injection, 3 ml of distilled water was added to each 1-g ampoule of cefamandole. The injection was given in the gluteal muscle through a 1.5-inch (ca. 3.8-cm) 20-gauge needle.
Probenecid. Commercially available tablets of probenecid (Benemid, Merck Sharp & Dohme, West Point, Pa.) were administered orally in a dose of 0.5 g 7 and 1 h before the injection.
Serum assays. Blood samples were drawn before and at intervals after the administration of single doses of cefamandole (see Table 1 ). The blood samples were centrifuged and the sera were frozen until assayed. Serum concentrations were measured using the Bacillus subtilis cup plate method (4). Urine assays. Urine was collected at the intervals shown in Table 2 . The urines were assayed by using an Elanco Autoturb (Elanco Products Co., Indianapolis, Ind.) with a Klebsiella strain as the indicator organisw.. Statistical analysis. A paired t test was used to test the hypothesis that the means for both treatment groups are the same versus the hypothesis that these means are different. This pairing was necessary since each patient in this study received each of the study medications. Figure 1 shows the average cefamandole blood levels achieved after the i.m. injection of 1 g of cefamandole alone compared with those obtained when 1 g of cefamandole was given to the same subjects after they had received probenecid orally. Figure 2 illustrates the alteration of cefamandole excretion by probenecid.
RESULTS
Probenecid administered orally in doses of 0.5 g every 6 h (for two doses) almost doubled the peak blood levels obtained after administration of 1 g of cefamandole: 37 and 20.4 ug/ml, respectively. The half-life was obviously prolonged by probenecid: 1.1 to 2 h; and at 8 h cefamandole could not be assayed in the blood after cefamandole alone, but after cefamandole plus probenecid, 2.9 gg/ml was found.
The higher and more prolonged levels seen with prebenecid plus cefamandole are related to the delay in excretion of cefamandole by the effect of probenecid on the kidney tubules. In Fig. 2 Probenecid is an organic acid that has a relaUsing the same formula, we found a renal tively high affinity for the renal tubular'trans-clearance of 229 ml/min per 1.73 m2 during the port system and is readily secreted with subse-2-to 4-h and 4-to 6-h urine collection periods. JH  750  190  143  2,205  150  353  1,564  110  172  392  110  43  TH  3,857  95  366  2,459  90  221  719  50  36  356  80  28  RM  1,780  115  205  1,898  120  228  800  130  104  313  90  28  AP  797  240  191  2,503  100  250  406  160  65  217  160  35   DW  1,520  210  319  3,050  60  183  810  80  65  267  60  16   RB  1,185  100  119  4,153  110  457  1,289  100  129  188  60  11  PM  938  300  281  1,313  260  341  492  170  84  267  60  16   ES  3,234  90  291  3,189  65  207  970  70  68  356  60  21   Mean  2,020  159  266  2,510  122  261  858  110  90  370  91  31   SDa  1,356  73  115  958  60  82  546  46  63  360  41  29 Cefamandole (1 g)  + probenecidb   AB  63  140  9  438  180  79  500  170  85  500  180  90  RD  813  310  252  500  280  140  1,039  240  249  1,477  150  222  ME  750  220  165  500  240 6 h, has been shown to adequately block penicillin (1) . This clearance rate of 57 ml for cefamandole when given with probenecid is similar to the rate of 75 ml reported by Kirby and Regamey for cefazolin without probenecid (5) . When probenecid is used, approximately 2% of the patients will have some noticeable degree of gastrointestinal irritation; hence, caution should be exercised if probenecid is administered to patients with known peptic ulcer (1) . In addition, skin rash has been reported in 2 to 4% of those taking probenecid (1) . Thus, it is difficult to differentiate the etiology of hypersensitivity should probenecid be given with another medication, a diagnostic dilemma not uncommon with the polytherapy of today.
In conclusion, the administration of probenecid, 0.5 g every 6 h orally, with cefamandole will almost double the blood levels and prolong the duration of therapeutic levels of cefaman-ANTIMICROB. AGENTS CHEMOTHER. dole by competitively blocking the renal tubular transport of cefamandole.
The higher and more prolonged blood levels of cefamandole associated with probenecid should permit the treatment of more serious clinical infections, including those due to relatively resistant organisms, or a reduction either in dose or in frequency of administration.
